CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.

CEL-SCI Trading Up 0.9 %

Shares of NYSE CVM opened at $0.40 on Thursday. The company has a quick ratio of 0.18, a current ratio of 0.64 and a debt-to-equity ratio of 1.00. The business has a fifty day simple moving average of $0.57 and a two-hundred day simple moving average of $0.92. The firm has a market cap of $29.84 million, a PE ratio of -0.69 and a beta of 0.65. CEL-SCI has a twelve month low of $0.36 and a twelve month high of $3.08.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Calton & Associates Inc. bought a new position in shares of CEL-SCI in the 3rd quarter worth $50,000. Plotkin Financial Advisors LLC bought a new position in shares of CEL-SCI in the 3rd quarter worth $98,000. Thoroughbred Financial Services LLC raised its position in shares of CEL-SCI by 140.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after acquiring an additional 80,001 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of CEL-SCI by 29.9% in the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after buying an additional 53,879 shares in the last quarter. 12.08% of the stock is owned by institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.